---

Management of Esophageal Malignancy by Location

---

Understanding the Basics First

• Upper 1/3 (Cervical): From cricopharyngeus to thoracic inlet (~8% of cancers)
• Middle 1/3 (Mid-thoracic): From thoracic inlet to tracheal bifurcation (~25%)
• Lower 1/3 (Lower thoracic + cardia): From carina to stomach (~67%)

• Upper & middle third: almost always squamous cell carcinoma (SCC)
• Lower third: usually adenocarcinoma (often on Barrett's esophagus)

---

Staging Summary (TNM)

---

UPPER THIRD (Cervical Esophagus) - 8% of cases

Key Features

• Almost always squamous cell carcinoma
• Unique lymphatic drainage: drains directly into paratracheal, deep cervical, and internal jugular nodes (not down into chest nodes)
• Very close to the larynx, trachea, and great vessels - this makes surgery risky and difficult
• Frequently unresectable at diagnosis because the tumor invades the larynx or trachea early

Treatment

1. Definitive Chemoradiotherapy (Treatment of Choice)

• Because of the high risk of surgery near the larynx/trachea/vessels, concurrent chemotherapy + radiation is the preferred approach for most patients
• Preserves the larynx (voice and swallowing)
• Regimen: cisplatin + 5-FU with radiotherapy

2. Surgery (Only for selected cases)

• Esophagolaryngectomy (removal of esophagus + larynx together) may be done occasionally when radiation fails or is not suitable
• This is a major, morbid operation with uncertain cure - so it is reserved for very few patients
• The patient would need a permanent tracheostomy and pharyngeal reconstruction

3. Neoadjuvant Chemotherapy Before Surgery

• Preoperative chemotherapy can shrink tumors near the carina/trachea, allowing a safer margin and permitting anastomosis to the cervical esophagus below the cricopharyngeus
• Without this, positive surgical margins often require laryngectomy to prevent recurrence

Simple Summary

Most patients with upper 1/3 cancer get chemoradiation, not surgery. Surgery is only for a few selected cases and carries high risk.

---

MIDDLE THIRD (Mid-thoracic Esophagus) - ~25% of cases

Key Features

• Almost always squamous cell carcinoma
• Lymph node spread can go in any direction - to the neck, chest, or abdomen, and can "skip" areas in between
• This makes it harder to completely clear all nodes

Treatment by Stage

Early (T1-T2, N0): Surgery Alone

• Surgical resection is the standard treatment
• Transthoracic esophagectomy (either open or minimally invasive) under direct vision is preferred for mid-esophageal tumors
• Options: VATS (video-assisted thoracic surgery) or conventional thoracotomy
• Most surgeons feel transhiatal approach (without opening the chest) is not ideal here - direct vision is better

Locally Advanced (T3, or any N+): Neoadjuvant Chemoradiation + Surgery

• When lymph nodes are involved or tumor has grown through the wall, chemoradiation is given first, followed by surgery 6-8 weeks later
• Cisplatin + 5-FU with radiation is the standard regimen
• This gives a 13% survival advantage over surgery alone
• Complete response rate (no tumor found in specimen): 17-24% for adenocarcinoma
• Goal: Get an R0 resection (tumor-free margins) - this is the most important predictor of long-term survival

Node Situations

• Abdominal lymph node metastases: generally considered incurable with surgery alone
• Isolated cervical lymph node metastases: emerging data suggest these can sometimes be resected with benefit

Surgical Techniques for Mid-Thoracic

• Three-field esophagectomy (minimally invasive): patient positioned left lateral, VATS approach, azygos vein divided, lymph nodes removed from upper/middle/lower posterior mediastinum, then laparoscopic abdominal phase + cervical anastomosis
• Ivor Lewis (en bloc) esophagectomy: laparotomy + right thoracotomy, radical lymph node dissection around celiac axis and mediastinum, intrathoracic anastomosis

Simple Summary

Early middle-third cancers = surgery. Advanced ones = chemoradiation first, then surgery. Direct vision (thoracoscopy/thoracotomy) is preferred over blind transhiatal approach.

---

LOWER THIRD (Lower Thoracic Esophagus + Cardia) - ~67% of cases

Key Features

• Usually adenocarcinoma (mostly arising on Barrett's esophagus)
• Submucosal spread is common - tumor cells can track far up the esophagus above what appears normal
• No lymphatic barrier between esophagus and stomach at the cardia
• Wong's rule: need at least a 10 cm margin of normal esophagus above the tumor to prevent anastomotic recurrence

Treatment

Unless Clearly Incurable: Resection is the Goal

• Surgical resection + lymph node dissection should be performed for all patients unless staging clearly shows incurable disease
• Because of submucosal spread, wide resection with generous margins is essential

Neoadjuvant Chemoradiation (for locally advanced)

• For locally advanced adenocarcinoma (T3 or N+), neoadjuvant chemoradiation is now standard in most centers
• MRC Trial (UK): Preoperative cisplatin + 5-FU gave a 10% absolute survival benefit at 2 years over surgery alone
• MAGIC Trial (UK): Epirubicin + cisplatin + 5-FU (ECF regimen) also showed survival advantage - now standard in Europe for locally advanced distal esophageal/gastric junction adenocarcinoma
• Surgery is done 6-8 weeks after finishing chemoradiation (too early = dangerous inflammation; too late = scarring makes dissection harder)

Surgical Approaches

1. Transhiatal esophagectomy - no chest opening, esophagus removed "blind" through the diaphragmatic hiatus, anastomosis in the neck
2. Ivor Lewis esophagectomy - abdominal + right thoracotomy, intrathoracic anastomosis in upper chest
3. Minimally invasive esophagectomy (MIE) - laparoscopic + thoracoscopic approach, reduces blood loss and recovery time
4. En bloc (radical) esophagectomy - extended lymph node clearance; no randomized proof of superiority but retrospective data show better survival with more nodes harvested

Simple Summary

Lower third cancers = surgery is the main treatment. For advanced cases, give chemoradiation first (6-8 weeks before surgery). Wide margins are essential. Adenocarcinoma is the dominant histology here.

---

Palliative Treatment (When Cure is Not Possible)

---

Quick Reference Summary Table

---

Key Principles to Remember

1. R0 resection (no tumor at margins) is the single most important factor for survival
2. Neoadjuvant chemoradiation improves survival over surgery alone in locally advanced disease
3. Surgery 6-8 weeks after completing chemoradiation is the optimal window
4. Gastric conduit is the standard replacement after esophagectomy
5. After incomplete (R1/R2) resection, 5-year survival is essentially 0%